PrintRESEARCH
Healthcare Reform Delivers a Bonanza for Biotechs
Podcast: April 19, 2010The Burrill Report (April 19, 2010): Healthcare Reform Delivers a Bonanza for Biotechs (.MP3,8.22 Mb)
During the debate over healthcare reform much of the biotechnology industry focused on what kind of damage, if any, the legislation would deliver. But tucked away in the massive bill was a little noticed provision that could provide a big boost to small companies. The Therapeutic Discovery Project Credit set aside $1 billion to provide a 50 percent tax credit to companies for qualified investments made in 2009 and 2010. We spoke to David Green, U.S. Life Sciences Tax leader for Deloitte, about the new credit, what it will mean to smaller biotechs, and what companies will need to do to claim their share.
[Please login to post comments]
- A Preventable Tragedy
Simple interventions could prevent the deaths of millions of delivering mothers, newborns, and children. Read More - New Insight to Arousal, But No Plans for a Female Viagra
Pfizer research points the way to possible treatments for sexual arousal disorder for women. Read More - Novartis Racing To Be First with Oral MS Drug
The company reveals additional encouraging data on its experimental treatment for multiple sclerosis. Read More - Javelin Bolts from Myriad for Hospira
Hospira sweeps in with richer offer for company with post operative pain drug pending regulatory approval. Read More - A Growing Controversy
Patents block competition, slow innovation in gene testing, researchers say. Read More - Astellas Unchallenged
With time running out on the Japanese company’s hostile bid, no counterbid is in sight. Read More - Abbott Must Turn Over CEO Emails to Prosecutors
The weekly round-up of failed trials, missed targets and other business mishaps. Read More - Convergence of Technology and Healthcare
Oracle acquires clinical trials data management company. Read More - BIO Readies to Address Big Issues in the City of Big Shoulders
Podcast: April 12, 2010 Read More - A Simple Twist of Fate
Stem cell therapeutics company buys Canada’s Verio Therapeutics. Read More
.gif)
| Burrill Select | NSDQ Biotech | BIOTECH |
923.97
-4.82 (-0.52%)
| Index | Last | Change (%) |
|---|---|---|
| Burrill Select | 923.97 | -4.82 (-0.52%) |
| NSDQ Biotech | 837.68 | -5.20 (-0.62%) |
| BIOTECH | 1052.01 | - (+0.00) |
| Amex Pharm | 271.23 | - (+0.00) |
| Nasdaq | 2257.04 | -20.64 (-0.91%) |
| S&P 500 | 1089.41 | - (+0.00) |
| NYSE | 6791.57 | -101.72 (-1.48%) |
| RUS 2K | 661.61 | -8.90 (-1.33%) |
Quotes delayed at least 20 mins.
Get Quote
- Cancer Fight: Unclear Tests for New Drug
The New York Times - Drug Sales May Advance to $1.1 Trillion on Emerging-Market Boom
Bloomberg - After Health Care Passage, Obama Pushes to Get It Rolling
The New York Times - Obama Health Team Turns to Carrying Out Law
The New York Times - Astellas Won’t Raise OSI Bid on FDA Decision Alone
Bloomberg - Test predicts effects of Amgen cancer drug
Reuters - Lilly First-Quarter Profit Falls on Health Overhaul
Bloomberg - Georgia Insurance Commissioner Balks at Request on New Health Law
The New York Times - DNA egg swap prevents rare diseases in babies
Reuters - Roche Shuns ‘Not Invented Here Syndrome’ to Boost Sales, Profit
Bloomberg